Vertex Pharmaceuticals
VRTX
503 hedge funds and large institutions have $18.9B invested in Vertex Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 198 increasing their positions, 180 reducing their positions, and 70 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 198 | Existing positions reduced: 180
0.66% more ownership
Funds ownership: 95.2% → 95.86% (+0.66%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
3% less funds holding
Funds holding: 518 → 503 (-15)
16% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 70
16% less call options, than puts
Call options by funds: $61.1M | Put options by funds: $72.7M
36% less capital invested
Capital invested by funds: $29.5B → $18.9B (-$10.7B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$559M |
| 2 |
Goldman Sachs
New York
|
+$139M |
| 3 |
O
OrbiMed
New York
|
+$108M |
| 4 |
GE
General Electric
Evendale,
Ohio
|
+$100M |
| 5 |
SIG
Senator Investment Group
New York
|
+$90.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$315M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$179M |
| 3 |
HCM
Hoplite Capital Management
New York
|
-$121M |
| 4 |
Jennison Associates
New York
|
-$93.1M |
| 5 |
JP Morgan Chase
New York
|
-$84.1M |
VRTX Hedge Fund Activity: Q1 2016 in Review
503 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2016, worth a combined $18.9B — down 36% from $29.5B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of VRTX and 59 opened new positions — a net loss of 11 holders — while 180 trimmed existing stakes and 198 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $559M. The largest seller was Winslow Capital Management, exiting entirely with an estimated $315M sold.
- 503 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2016, down from 518 in Q4 2015.
- Funds reported $18.9B of Vertex Pharmaceuticals stock for Q1 2016, down 36% quarter-over-quarter.
- 59 funds opened new Vertex Pharmaceuticals positions in Q1 2016 and 70 closed out, a net change of -11 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2016 was T. Rowe Price Associates, an estimated $559M added.
- The largest Vertex Pharmaceuticals seller in Q1 2016 was Winslow Capital Management, an estimated $315M sold.
Based on aggregated 13F filings for Q1 2016.